MEDICINE AND
暂无分享,去创建一个
J. Struewing | M. Tucker | A. Goldstein | D. Hogg | Ling Liu | M. Shennan | Chair man Milwaukee Wis Brown | Alisa M. Goldstein | Margaret A. Tucker | Michael Shennan | Chairman Baltimore Md. W. H Howell | Dr. John M. T. Finney | Dr. Alexander C. Abbott | Philadelphia Pa Section Chair man | L. PharmacyDr.David | Philadelphia Pa Edsall Chairman | Dr. Samuel H. Gilliland | I. DentalDr.GeorgeV. | Section | Ling Liu | David Hogg | J. P. Struewing | Chairman Baltimore Md. W. H Howell | Dr. John M. T. Finney | Dr. Alexander C. Abbott | Philadelphia Pa Section Chair man | L. PharmacyDr.David | Philadelphia Pa Edsall Chairman | Dr. Samuel H. Gilliland | I. DentalDr.GeorgeV. | Chair man Milwaukee Wis Brown | Section
[1] Å. Borg,et al. Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families , 2001, Genes, chromosomes & cancer.
[2] J. Struewing,et al. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. , 2000, American journal of human genetics.
[3] J. Struewing,et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. , 2000, Journal of the National Cancer Institute.
[4] P. Bruzzi,et al. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia , 1999, International journal of cancer.
[5] M. Tucker,et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] X. Estivill,et al. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia , 1999, Journal of medical genetics.
[7] D. Bishop,et al. Mutation testing in melanoma families: INK4A, CDK4 and INK4D , 1999, British Journal of Cancer.
[8] L. Chin,et al. Malignant melanoma: modern black plague and genetic black box. , 1998, Genes & development.
[9] R. MacKie,et al. CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. , 1998, The Journal of investigative dermatology.
[10] M. King,et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. , 1998, American journal of human genetics.
[11] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[12] Yue Xiong,et al. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.
[13] D. Stoppa-Lyonnet,et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. , 1998, Human molecular genetics.
[14] G. Peters,et al. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma , 1996, Molecular and cellular biology.
[15] Å. Borg,et al. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. , 1996, Cancer research.
[16] L. Sandkuijl,et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds , 1995, Nature Genetics.
[17] H. Varmus,et al. Mutations associated with familial melanoma impair p16INK4 function , 1995, Nature Genetics.
[18] R. DePinho,et al. Inhibition of ras-induced proliferation and cellular transformation by p16INK4 , 1995, Science.
[19] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[20] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[21] D. Bishop,et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. , 2001, Human molecular genetics.
[22] David Hogg,et al. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma , 1999, Nature Genetics.
[23] P. Pollock,et al. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations , 1998, Human mutation.
[24] M. King,et al. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. , 1996, American journal of human genetics.
[25] M. Tucker,et al. Familial melanoma and its management , 1996 .